ACLARION INC
NASDAQ: ACONW (Aclarion Inc)
Last update: 16 hours ago0.029
0.01 (35.51%)
| Previous Close | 0.021 |
| Volume | 70,421 |
| 52 Weeks Range |
| Operating Margin (TTM) | -10,789.22% |
| Diluted EPS (TTM) | -6.58 |
| Quarterly Revenue Growth (YOY) | 78.10% |
| Total Debt/Equity (MRQ) | 47.32% |
| Current Ratio (MRQ) | 14.17 |
| Operating Cash Flow (TTM) | -8.95 M |
| Levered Free Cash Flow (TTM) | -5.60 M |
| Return on Assets (TTM) | -45.78% |
| Return on Equity (TTM) | -74.07% |
AIStockmoo Score
| Value 43% | -0.4 |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Return on Capital info | NA |
| Earnings Trend info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing | NA |
| From our AI technical analysis of the chart. info | NA |
| Trend Strength info | NA |
| Technical Setup info | NA |
| Candle Patterns info | NA |
| Medium-Term Trend info | NA |
| Sentiment 29% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Holdings' Sentiment info | NA |
| News Mood info | NA |
| Smart Money 29% | -0.8 |
| Short interest +16.8% from 31 Aug to 30 Oct 2026, 7.1 days to cover (FINRA). info | |
| Insider Activity info | NA |
| Institutional Flow info | NA |
| Market and sector conditions are favourable. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| Only one pillar has a clear reading, so the score is unchanged. | |
| Not in score | |
| Price Volatility info | NA |
| No clear trend across the short, medium and long term. info | |
| No clear signal from support and resistance. info | |
| Final Score | -0.39 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Mixed | Bearish |
| Health Information Services (Global) | Mixed | Bearish | |
| Stock | Aclarion Inc | - | - |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| ACONW | - | - | - | - | -0.4 |
| CARL | 477 M | - | - | 6.29 | 1.6 |
| SY | 166 M | - | - | 0.770 | -2.9 |
| OTRKP | - | - | - | - | -2.9 |
| TEM | 10 B | - | - | 19.68 | -0.1 |
| HQY | 8 B | - | 34.21 | 4.05 | 0.0 |
Select this tab to load the latest available analysis.
|
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. The company develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in Broomfield, Colorado. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Captrust Financial Advisors | 30 Sep 2026 | 63,400 |
No data within this time range.
Institutions
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 81,593 | 7.1 |
| 15 Oct 2026 | 73,843 | 4.2 |
| 30 Sep 2026 | 67,490 | 5.6 |
| 15 Sep 2026 | 66,327 | 27.1 |
| 31 Aug 2026 | 69,875 | 8.3 |
| 14 Aug 2026 | 231,797 | 4.2 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 28 Oct 2026 | Yahoo Finance |
Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimates
Bausch + Lomb (BLCO) delivered earnings and revenue surprises of +61.91% and +0.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 27 Oct 2026 | Yahoo Finance |
HCA Healthcare (HCA) Q3 Earnings and Revenues Top Estimates
HCA (HCA) delivered earnings and revenue surprises of +7.12% and +2.50%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 22 Oct 2026 | Yahoo Finance |
Aclarion Announces New Real-World Publication: Nociscan® Validated by Strong Agreement with Discography in Diagnosing Painful Lumbar Discs
Study conducted at London Spine Clinic found Nociscan's noninvasive scan successfully identified painful discs, agreeing with discography, the invasive gold standard, in up to 87% of casesNociscan also spared patients the needles, added cost, and recovery time that is often associated with… |
| 20 Oct 2026 | Yahoo Finance |
Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026
85% year-over-year scan volume growth in Q3 2026, contributing to 117% growth for the nine months ended September 30, 2026European Spine Journal publishes peer-reviewed data supporting MRS as a potential viable alternative to provocative discographyCLARITY trial expanded to eleven clinical sites… |
| 13 Oct 2026 | Yahoo Finance |
Aclarion to Present at the 20th Annual LD Micro Main Event
BROOMFIELD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion (NASDAQ: ACON) announced today that it will participate in the 20th Annual LD Micro Main Event, taking place October 19-21, 2026 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. Aclarion is scheduled to present on Tuesday… |
| 08 Oct 2026 | Yahoo Finance |
Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
New criteria fully approved at nine of eleven active sites expected to significantly accelerate enrollment paceInitial readout timing to be updated by year-end based on demonstrated Q4 enrollment increasesOverall trial duration remains on track BROOMFIELD, Colo., Oct. 08, 2026 (GLOBE NEWSWIRE)… |
| 29 Sep 2026 | Yahoo Finance |
Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical researchCLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical… |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |